Treating Patients With Breast Cancer After Progression on Endocrine Therapy

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, looks at options for a patients with hormone receptor–positive, HER2-negative breast cancer and an ESR1 mutation in the second article of a 2-part series.

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.

During a Case-Based Roundtable® event, William J. Gradishar, MD, discussed how elacestrant benefited several subgroups of patients with metastatic breast cancer who were positive for an ESR1 mutation, along with practical considerations when addressing toxicities that arise with therapy in the second article of a 2-part series.

In the first article in a 2-part series, William J. Gradishar, MD, discusses the importance of elacestrant for treating patients with ESR1 positive metastatic breast cancer.

In the second article of a 2-part series, Komal Jhaveri, MD, leads a discussion on the considerations physicians must have when looking to give elacestrant to patients with estrogen receptor–positive, HER2 negative metastatic breast cancer.

In the first article of a 2-part series, Komal Jhaveri, MD, guides a conversation on treatment options for patients with ESR1-positive metastatic breast cancer.

In the second article of a 2-part series, Hope S. Rugo, MD, FASCO, leads a conversation on the results of the EMERLAD study that showed elacestrant’s longer survival outcomes against standard of care endocrine therapy for patients with HR+, HER2- metastatic breast cancer.

In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.

In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.

In this first part of a 2-article series, Joyce O’Shaughnessy, MD, recent updates to treatment and testing guidelines for patients with advanced breast cancer whose disease harbors an ESR1 mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed the use of elacestrant for patients who have received prior endocrine therapy for ER-positive, HER2-negative breast cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.

Sara Hurvitz, MD, discusses updates of the EMERALD trial investigating elacstrant vs the standard of care, including the subgroups of patients who received prior CDK4/6 inhibition for 6, 12, or 18 months.

Sara Hurvitz, MD, discusses recent updates for selective estrogen receptor degraders in the treatment of patients with metastatic breast cancer and how it has impacted clinical decisions.